Multinational drugmakers make big price cuts to be covered in China list

29 November 2019

Multinationals pharmaceutical companies have cut prices significantly for some of the bestselling drugs in China to get covered by China’s newly-updated reimbursement drug list, effective on January 1 ,2020, reports The Pharma Letter’s local correspondent, Wang Fangqing.

According to the Chinese National Healthcare Security Administration (NHSA), the new list covers 2,705 drugs, 64 more than the previous 2017 list. The 2019 list includes 22 cancer treatments, seven rare disease drugs and 14 for chronic diseases like diabetes and rheumatoid arthritis. 70 drugs were new to the list, with an average price cut at 60.7%.

Significant price cuts were seen among cancer drugs. For example, AbbVie (NYSE: ABBV) cut the price of Humira (adalimumab) to 1,290 renminbi ($183.7) per unit (40mg/0.4ml), compared to the average retail price around 3,160 renminbi. AstraZeneca’s (LSE: AZN) diabetes drug Farxiga (dapagliflozin) is priced at 4.36 renminbi per tablet (10mg) in the list, down 69% from the retail price 14.3 renminbi.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK